Affini-T Therapeutics Completes $175 Million Financing Co-Led By Vida Ventures And Leaps By Bayer To Advance Groundbreaking T Cell Therapies For Solid Tumor Patients With Oncogenic Driver Mutations
Affini-T Therapeutics Completes $175 Million Financing Co-Led By Vida Ventures And Leaps By Bayer To Advance Groundbreaking T Cell Therapies For Solid Tumor Patients With Oncogenic Driver Mutations
03/22/22, 11:30 AM
Location
bostonMoney raised
$175 million
Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the completion of an oversubscribed $175 million financing co-led by Vida Ventures and Leaps by Bayer, the impact investment unit of Bayer. Additional investors participating in the round include Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, Fred Hutchinson Cancer Research Center and other leading blue chip life science investors. With proceeds from this financing, the company will operationalize its platform discovery engine and seek to drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. To enable and accelerate growth, the company has established a bi-coastal U.S
Company Info
Location
boston, massachusetts, united states
Additional Info
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Its differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. The company leverages these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in its leadership team, founders and technologies, Affini-T is powered to develop transformational medicines that last.